Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update
August 15, 2022
Biotechnology
-
-
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
August 15, 2022
-
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA(TM) in Combination with Tagrisso® in Non-Small Cell Lung Cancer
August 15, 2022
-
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
August 15, 2022
-
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
August 11, 2022
-
Acasti Pharma Reports First Quarter 2023 Operational Results
August 11, 2022
-
Todos Medical Completes Trial Design for Tollovid(TM) Long COVID Clinical Study in Adults
August 11, 2022
-
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
August 11, 2022
-
Oncocyte Reports Second Quarter 2022 Financial Results
August 10, 2022
-
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
August 10, 2022
-
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
August 10, 2022
-
MannKind Corporation Reports 2022 Second Quarter Financial Results
August 9, 2022
-
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
August 8, 2022
-
Evofem Biosciences Strengthens Board of Directors
August 3, 2022
-
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
August 3, 2022
-
Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign
August 2, 2022